Create Medicines raised $122 million in a Series B round to advance its in vivo CAR therapies, spanning autoimmune disease and oncology. The company’s approach uses an mRNA-LNP platform to engineer T cells, NK cells, and myeloid cells inside the body, aiming for scalable, repeat-dose, off-the-shelf immunotherapies. The financing signals investor confidence in delivering whole-body immune engineering rather than ex vivo cell manufacturing. Create Medicines framed the funding as support for pipeline progression across multiple indications and next-stage development work for its lead programs. The round also adds momentum to the in vivo CAR category as companies compete to demonstrate consistent potency, durability, and controllability in human trials.